SCN Signs LOI with US Partner Regarding Coldizin Launch

Scandinavian Clinical Nutrition AB (SCN) has signed a Letter of Intent with the company’s US partner Inverness Medical Innovations, Inc. regarding mass market launch of the cold product Coldizin in USA.

As a part of ongoing negotiations regarding launch of SCN’s patented and trademark protected cold product Coldizin in USA, SCN has signed a Letter of Intent (LOI) with the company’s mass market partner Inverness Medical Innovations, Inc. The objective of the negotiations is to agree on terms for launching Coldizin in the fall of 2008 on the US mass market.